

Journal Pre-proof



Bergamot leaf extract treats cardiorenal metabolic syndrome and associated pathophysiological factors in rats fed with a high sugar fat diet

Juliana Silva Siqueira, Taynara Aparecida Vieira, Erika Tiemi Nakandakare-Maia, Thiago Luiz Novaga Palacio, Felipe Sarzi, Jessica Leite Garcia, Bruno Henrique de Paula, Silmeia Garcia Zanati Bazan, Giovanna Baron, Luigi Tucci, Elzbieta Janda, Alessandra Altomare, Francesca Gado, Artur Junio Togneri Ferron, Giancarlo Aldini, Fabiane Valentini Francisqueti-Ferron, Camila Renata Correa

PII: S0303-7207(22)00169-1

DOI: <https://doi.org/10.1016/j.mce.2022.111721>

Reference: MCE 111721

To appear in: *Molecular and Cellular Endocrinology*

Received Date: 31 May 2022

Revised Date: 2 July 2022

Accepted Date: 7 July 2022

Please cite this article as: Silva Siqueira, J., Aparecida Vieira, T., Tiemi Nakandakare-Maia, E., Luiz Novaga Palacio, T., Sarzi, F., Leite Garcia, J., Henrique de Paula, B., Garcia Zanati Bazan, S., Baron, G., Tucci, L., Janda, E., Altomare, A., Gado, F., Togneri Ferron, A.J., Aldini, G., Valentini Francisqueti-Ferron, F., Renata Correa, C., Bergamot leaf extract treats cardiorenal metabolic syndrome and associated pathophysiological factors in rats fed with a high sugar fat diet, *Molecular and Cellular Endocrinology* (2022), doi: <https://doi.org/10.1016/j.mce.2022.111721>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 Published by Elsevier B.V.



CRediT author statement

Juliana Silva Siqueira: Conceptualization, Data Curation, Methodology, Project administration, Writing original draft; **Taynara Aparecida Vieira:** Methodology; **Erika Tiemi Nakandakare-Maia:** Methodology; **Thiago Luiz Novaga Palacio:** Methodology; **Felipe Sarzi:** Methodology; **Jessica Leite Garcia:** Methodology; **Bruno Henrique de Paula:** Methodology; **Silméia Garcia Zanati Bazan:** Methodology; **Giovanna Baron:** Methodology, Conceptualization; **Luigi Tucci:** Methodology; **Elzbieta Janda:** Methodology; **Alessandra Altomare:** Methodology; **Francesca Gado:** Methodology; **Artur Junio Togneri Ferron:** Conceptualization, Data Curation; **Giancarlo Aldini:** Conceptualization, Funding acquisition, Writing original draft; **Fabiane Valentini Francisqueti-Ferron:** Conceptualization, Data Curation, Supervision, Project administration, Writing original draft; **Camila Renata Correa:** Conceptualization, Data Curation, Funding acquisition, Supervision, Project administration, Writing original draft.

Signature

1 **Bergamot leaf extract treats cardiorenal metabolic syndrome and associated pathophysiological factors in**
2 **rats fed with a high sugar fat diet**

3
4 **Authors:** Juliana Silva Siqueira^{a,*}; Taynara Aparecida Vieira^a; Erika Tiemi Nakandakare-Maia^a; Thiago Luiz
5 Novaga Palacio^a; Felipe Sarzi^a; Jessica Leite Garcia^a; Bruno Henrique de Paula^a; Silmeia Garcia Zanati Bazan^a;
6 Giovanna Baron^b; Luigi Tucci^c; Elzbieta Janda^d; Alessandra Altomare^b; Francesca Gado^b; Artur Junio Togneri
7 Ferron^{a,e}; Giancarlo Aldini^b; Fabiane Valentini Francisqueti-Ferron^{a,e}; Camila Renata Correa^a.

8
9 ^a São Paulo State University (Unesp), Medical School, Botucatu 18618687, Brazil

10 ^b Department of Pharmaceutical Sciences, University of Milan, 20133 Milan, Italy

11 ^c H&AD Srl, 89032 Bianco, Italy;

12 ^d Department of Health Sciences, University “Magna Graecia” of Catanzaro, 88100 Catanzaro, Italy

13 ^e Integrated Colleges of Bauru (FIB), 17056-100, Brazil

14
15
16 * Corresponding author

17 Juliana Silva Siqueira, Botucatu Medical School, São Paulo State University (Unesp), Professor Montenegro
18 Avenue, Botucatu 18618687, Brazil

19 Tel.: +55 11 9614660651.

20 E-mail address: juliana.siqueira@unesp.br (J.S. Siqueira).

21
22 Declarations of interest: none

23
24 **Abstract**

25 Bergamot citrus (*Citrus bergamia* Risso et Poiteau), have been used as a strategy to prevent or treat
26 comorbidities associated with metabolic syndrome parameters, such as cardiorenal metabolic
27 syndrome (CRMS). The aim was to test the effect of bergamot leaf extract on CRMS and associated
28 pathophysiological factors in rats fed with a high sugar-fat diet. Animals were divided into two
29 experimental groups with control diet (Control, $n=30$) and high sugar-fat diet (HSF, $n=30$) for 20 weeks.
30 Once CRMS was detected, animals were redivided to begin the treatment with Bergamot Leaf Extract
31 (BLE) by gavage (50mg/Kg) for 10 weeks: control diet + placebo (Control, $n=09$), control diet + BLE
32 (Control+BLE, $n=09$), HSF diet + placebo (HSF, $n=09$), HSF + BLE ($n=09$). Evaluation included
33 nutritional, metabolic and hormonal analysis; and renal and cardiac parameters. HSF groups presented
34 obesity, dyslipidemia, hypertension, hyperglycemia, hyperinsulinemia, insulin resistance. BLE showed
35 protection against effects on hypertriglyceridemia, insulin resistance, renal damage, and structural and
36 functional alterations of the heart. Conclusion: Bergamot leaf extract shows potential as a therapeutic
37 to treat CRMS in animals fed with a high sugar-fat diet.

38
39
40
41 Key words: Bergamot, CRMS, Western diet, metabolic syndrome

52 **1. Introduction**

53 In recent decades, the Western lifestyle demands more practical and quick meals, usually composed by
54 industrialized products with high energy density and rich in sugars and fats, which associated to physical
55 inactivity, resulting in positive energy balance resulting in adipose tissue expansion and, consequently, obesity
56 (Popkin et al., 2012). The adipose tissue expansion due to adipocyte hypertrophy causes an imbalance in the
57 secretion of adipokines which are associated with several complications and diseases, such as insulin resistance,
58 hypertension, dyslipidemia and chronic inflammation, all risk factors for cardiorenal metabolic syndrome
59 (CRMS)(Rangaswami et al., 2019)(Whaley-Connell and Sowers, 2014)

60 In addition to hypertrophy, consumption of high sugar-fat diets can cause mitochondrial stress leading to an
61 increase in reactive oxygen species (ROS) and a decrease in antioxidant capacity, by inhibiting the nuclear factor
62 erythroid 2 related factor 2 (Nrf2), a transcription factor that plays a crucial role in the maintenance of redox and
63 metabolic homeostasis in response to reactive species and inflammation by regulating genes involved in the
64 response against oxidative stress, promoting redox homeostasis(Cuadrado et al., 2018; Echeverría et al., 2018;
65 Wu et al., 2021). Thus, the redox imbalance scenario favors CRMS and contributes to the development of
66 complications that trigger this syndrome.

67 The CRMS, defined as combined disorders of heart and kidney, is characterized by impaired coronary blood
68 flow, impaired diastolic relaxation, impaired ischemic preconditioning, renal hyper-filtration, proteinuria,
69 glomerular sclerosis, tubule-interstitial fibrosis, and decreased GFR (glomerular filtration rate), with significant
70 impact on life expectancy and mortality(Francisqueti et al., 2017; Rangaswami et al., 2019; Silva Junior et al.,
71 2017; van der Velde et al., 2011; Whaley-Connell and Sowers, 2014). In order to prevent or treat cardiorenal
72 metabolic syndrome, it is important to consider treatment strategies for modulating the pathophysiological
73 processes involved in this disease. Within this context, researches about the effect of bioactive compounds present
74 in natural products, as fruits, have been emerged mainly because these compounds have anti-inflammatory
75 capacity, modulating the macrophage profile, and antioxidants acting as scavengers or stimulators of
76 Nrf2(Gugliandolo et al., 2020).

77 Bergamot citrus (*Citrus bergamia Risso et Poiteau*) has shown antioxidant and anti-inflammatory
78 potential(Formisano et al., 2019). In addition, studies also report to be effective in treating metabolic syndrome
79 parameters, especially due the hypolipemic and hypoglycemic effect(Mollace et al., 2011; Risitano et al., 2014).
80 These benefits are attributed to the polyphenolic fraction of bergamot fruit that consists predominantly of
81 flavonoids (naringin, neo-peridin, neoeriocitrine, brutieridin and melitidine)(Di Donna et al., 2009). However,
82 investigations show that for some plants, the phenolic composition of the leaf can be similar or even higher than
83 the fruit, indicating that they may be used as an alternative source for the development of food supplements,
84 nutraceuticals or functional foods(Baron et al., 2021; Ferlemi and Lamari, 2016).

85 Based on this, Baron et al (2021), conducted a study characterizing the bioactive compounds present in the
86 leaf and fruit extract of bergamot. The results showed that the leaves have a higher amount of polyphenols and a
87 greater antioxidant and anti-inflammatory capacity *in vitro*(Baron et al., 2021). Thus, since there are no studies
88 that evaluated the effect of bergamot leaf extract on metabolic parameters neither in cardiorenal metabolic
89 syndrome *in vivo* model, this investigation becomes original and extremely relevant. In addition, because the
90 bergamot fruit is a valuable raw material that is in high demand, has many applications, and is cultivated in a
91 limited region of Southern Italy, the opportunity to identify the leaves as a source of bioactive polyphenols with

92 a chemical and bioactive profile overlapping that of fruit polyphenols, allows for the availability of a renewable
93 and low cost source for this important raw material. These results may lead to a sustainable product with
94 pharmacological action to attenuate Cardiorenal Metabolic Syndrome. Therefore, the aim of this study was to test
95 the effect of bergamot leaf extract on Cardiorenal Metabolic Syndrome and associated pathophysiological factors
96 in rats fed with a high sugar-fat diet.

97

98 2. Materials and Methods

99 2.1. *Experimental Protocol and Groups Characterization*

100 The experiments and procedures were approved by the Animal Ethics Committee (271/2021) and were
101 performed in accordance with the National Institute of Health's Guide for the Care and Use of Laboratory
102 Animals. Male Wistar rats (± 187 g) were kept in an environmental controlled room ($22 \text{ }^\circ\text{C} \pm 3 \text{ }^\circ\text{C}$; 12 h light-dark
103 cycle and relative humidity of $60 \pm 5\%$) and randomly distributed into 2 experimental groups by 20 weeks. During
104 this period, the animals received, ad libitum, a control diet + water (Control, $n = 30$) and high sugar-fat diet +
105 water containing 25% sucrose (HSF, $n = 30$). The diets were designed in our laboratory and previously
106 published (Francisqueti et al., 2017). After this period, when CRMS was detected- determined by cardiac
107 dysfunction and stage 0 of renal disease (Romão Junior, 2004) the presence of renal disease risks detected, a 95%
108 confidence interval (CI) was built for the cardiac dysfunction and risk factors for renal diseases from the HSF and
109 control groups. Was adopted as the separation point (SP) between the groups, the midpoint between the upper
110 limit of the control group and the lower limit of the HSF group. From the data, the CRMS was
111 characterized (Rangaswami et al., 2019; Whaley-Connell and Sowers, 2014). This criterion was adopted because
112 animals submitted to different diet models do not always present the expected response. This fact can lead to
113 erroneous animal classification and, consequently, false conclusions. Accomplished, these animals were randomly
114 redistributed into 4 experimental groups: control diet + placebo (Control, $n=09$), control diet + bergamot leaf
115 extract (Control+BLE, $n=09$), high sugar-fat diet + placebo (HSF, $n=09$), high sugar-fat diet + bergamot leaf
116 extract (HSF+BLE, $n=09$). This procedure was performed over a period of 10 weeks to verify the effect of the
117 treatment of bergamot leaf extract on cardiorenal metabolic syndrome. The animals that didn't developed CRMS
118 were excluded from the experiment.

119

120 2.2. *Bergamot leaf extract (BLE)*

121 The bergamot leaves were harvested in a farm located in the Reggio Calabria region, Italy, and the dry
122 extract was obtained at H&AD (Herbal & Antioxidant Derivatives S.r.l.) plant located in Località Chiusi, 89032
123 Bianco (RC), Italy (www.head-sa.com). The leaves were immediately chopped and added to a solution of water /
124 ethanol (30/70 % v / v) to extract the polyphenols. The extraction procedure was repeated twice for one hour and
125 the resulting solution was distilled to recover the ethanol. The clarified water solution was passed through a layer
126 of absorbent polystyrene resins with pores with a diameter between 100 and 150 Ångstrom to retain polyphenols,
127 which were subsequently eluted from the resin bed flowing pure ethanol. Then, the obtained ethanol solution was
128 distilled in vacuum at temperatures of up to 40°C , obtaining a concentrate containing residual water and
129 polyphenols, which were dried in a spray drying system, obtaining a powder with moisture content less than 4.0%.

130 The administration was carried out daily by gavage, at a concentration of 50mg/Kg of weight and the
131 extract was diluted in filtered water. The dose was established according to literature data that use this
132 concentration from fruit juice, as there are no studies using leaf extract(Musolino et al., 2020).

134 **2.3. Nutritional, Metabolic and Hormonal Analysis**

135 The nutritional profile was evaluated according to caloric intake, body weight and adiposity index.
136 Calorie intake was determined by multiplying the energy value of each diet ($g \times Kcal$) by the daily food intake.
137 For the HSF group, it also included calories from water ($0.25 \times 4 \times mL$ consumed). The animals' body weight
138 was evaluated weekly. The adiposity index was used as an indicator of obesity at 30th week, since it accurately
139 assesses the amount of body fat in the animals. After euthanasia, the epididymal, visceral and retroperitoneal fat
140 deposits were dissected from the animals. The sum of deposits normalized by body weight
141 [(epididymal+retroperitoneal+visceral)/body weight $\times 100$] is considered the adiposity index(Luvizotto et al.,
142 2013).

143 After 8-h fasting, blood was collected and the plasma was used to measure insulin and biochemical
144 parameters. Glucose concentration was determined by using a glucometer (Accu-Chek Performa; Roche
145 Diagnostics, Indianapolis, IN, USA); triglycerides levels were measured with an automatic enzymatic analyzer
146 system (Chemistry Analyzer BS-200, Mindray Medical International Limited, Shenzhen, China). The insulin level
147 was measured using the enzyme-linked immunosorbent assay (ELISA) method using commercial kits (Linco
148 Research Inc., R&D Systems, Millipore e B-Brigde International Inc.) and the reading was performed in a
149 Spectramax 190 microplate spectrophotometer (Molecular Devices®, Sunnyvale, CA, USA). The homeostatic
150 model of insulin resistance (HOMA-IR) was used as an insulin resistance index, calculated according to the
151 formula: $HOMA-IR = (\text{fasting glucose (mmol/L)} \times \text{fasting insulin } (\mu\text{U/mL}))/22.5$ (Matthews DR, Hosker JP,
152 Rudenski AS, Naylor BA, Treacher DF et al., 1985).

154 **2.4. Systolic Blood Pressure**

155 Systolic blood pressure (SBP) evaluation was assessed in conscious rats by the non-invasive tail-cuff
156 method with a NarcoBioSystems® Electro-Sphygmomanometer (International Biomedical, Austin, TX, USA).
157 The animals were kept in a wooden box (50×40 cm) between $38-40$ °C for 4–5 min to stimulate arterial
158 vasodilation(Gonc et al., 2014). After this procedure, a cuff with a pneumatic pulse sensor was attached to the tail
159 of each animal. The cuff was inflated to 200 mmHg pressure and subsequently deflated. The blood pressure values
160 were recorded on a Gould RS 3200 polygraph (Gould Instrumental, Valley View, OH, USA). The average of three
161 pressure readings was recorded for each animal.

163 **2.5. Renal Function**

164 Plasma and urine were used to evaluate the renal function. During 12 hours, urine was collected through
165 metabolic cages for further analysis of total protein and creatinine using commercial colorimetric kits (CELM®
166 kits, Barueri, São Paulo, Brazil). To assess kidney damage, proteinuria through protein/creatinine ratio was
167 determined; glomerular filtration rate (GFR) = $((\text{urine creatinine} \times \text{flux})/\text{plasma creatinine})$ was calculated as
168 marker of kidney function(Anna et al., 2010).

170 **2.6. Structural and Functional Cardiac Function**

171 Doppler echocardiographic evaluation was performed by a single examiner at the 20th and 30th weeks.
172 Animals were anesthetized with ketamine (50 mg/kg, i.p.) and xylazine hydrochloride (1 mg/kg, i.p.). After
173 trichotomy of the anterior chest region, the animals were placed in slight left lateral decubitus for the exam. The
174 equipment used was model Vivid S6 (General Electric Medical Systems, Tirat Carmel, Israel) with a
175 multifrequency ultrasonic transducer 5.0 to 11.5 MHz. To implement structural measurements of the heart, the
176 images were obtained in one-dimensional mode (M-mode) guided by the images in two-dimensional mode with
177 the transducer in the parasternal position, minor axis.

178 Left ventricular (LV) evaluation was performed by positioning the cursor M-mode just below the mitral
179 valve plane at the level of the papillary muscles. The images of the aorta and left atrium were obtained by
180 positioning the M-mode course to plan the level of the aortic valve. The following cardiac structures were used to
181 analyze cardiac morphology: left ventricular diastolic diameter (LVDD); left ventricular systolic diameter
182 (LVSD); left atrium (LA); LA/AO; relative wall thickness (RWT). The LV systolic function was assessed by the
183 following parameters; endocardial fractional shortening (FS%) $((LVDD - LVSD)/LVDD) \times 100$; posterior wall
184 shortening velocity (PWSV). The LV diastolic function was evaluated using the following indices: peak velocity
185 of early diastolic filling (E wave). The study was supplemented by evaluation by tissue Doppler systolic
186 displacement (S'), early diastolic (E') and late (A') of the mitral annulus (arithmetic average travel speeds of lateral
187 and septal walls), and E/A and E/E' wave ratios.

188 The LV systolic function was assessed by the following parameters: Left ventricle posterior wall
189 shortening velocity (LVPWSV) and endocardial fractional shortening (EFS%) $((LVDD - LVSD)/LVDD) \times 100$.
190 The LV diastolic function was evaluated using the following indices: E/E' ratio and E wave deceleration time
191 (EWDt). The study was supplemented by evaluation by tissue Doppler systolic displacement (S'), early diastolic
192 (E') and late (A') of the mitral annulus (arithmetic average travel speeds of lateral and septal walls), and E/E' wave
193 ratios (Sahn et al., 1978).

194 **2.7. Nrf2 activation**

196 The bergamot leaf ability to modulate the antioxidant response pathway induced by Nrf2 activation was
197 tested using NRF2/ARE Responsive Luciferase Reporter HEK293 stable cell line (Signosis, Santa Clara, CA,
198 USA). Cells were grown in Dulbecco modified Eagle medium (DMEM; Lonza, Verviers, Belgium) supplemented
199 with 10% fetal bovine serum (FBS; Gibco, Gaithersburg, MD, USA), 1 % Penicillin/Streptomycin (Lonza) and
200 50 µg/mL of G418 sulfate solution (Promega Corporation, Madison, WI, USA). HEK293 cells were treated with
201 different concentrations (100, 150, 200 and 250 µg/ml) of BLE for 18 h after seeding in white 96-well plate
202 (BRANDplates®, cell grade) at 10000 cells/well. Subsequently, to avoid any interference on the reading of
203 luciferase activity, media was removed and 100 µL/well of PBS was added. ONE-Glo™ Luciferase Assay
204 Substrate (purchased from Promega Corporation, Madison, WI, USA) (100 µL/well) was directly added to the
205 wells, followed by a luciferase measurement performed using a luminometer (Wallac Victor2 1420, Perkin-
206 Elmer™ Life Science, Monza, Italy). Experiments were performed with biological and technical replicates; values
207 are shown as mean ± SD compared to untreated control cells. Statistical analysis was performed using one-way
208 ANOVA with Bonferroni's multiple comparisons test ($p < 0.05$ was considered significant).

209 The cell viability was assessed with MTT assay on HEK293 cells treated with all the concentrations of
210 the BLE as reported previously (Baron et al., 2021).

211

212 **2.8. Statistical Analysis**


213 Data are presented as means \pm standard deviation (SD) or medians (interquartile range). Differences
214 among the groups were determined by two-way analysis of variance. Statistically significant variables were
215 subjected to the two-way ANOVA test with Tukey post-hoc. Statistical analyses were performed using Sigma
216 Stat for Windows Version 3.5. (Systat Software, Inc., San Jose, CA, USA). A p value of 0.05 was considered as
217 statistically significant.

218

219 **3. Results**

220 ***Nutritional and metabolic parameters: triglycerides, insulin and insulin resistance were attenuated***
221 ***with 10 weeks of treatment with BLE.***

222 The HSF diet promoted increased caloric intake, adiposity index, final body weight, systolic blood
223 pressure and blood glucose, characterizing an experimental model of obesity accompanied by comorbidities that
224 are risk factors for cardiorenal metabolic syndrome. These parameters were not attenuated with the treatment of
225 bergamot leaf extract (Figure 1 A, B, C, D and F). On the other hand, triglycerides, insulin and insulin resistance
226 were also found to be elevated in the HSF group, but were attenuated by the extract treatment (Figure 1 E, G and
227 H).




228

229 **Figure 1.** Nutritional, metabolic and hormonal analysis in the 30th week. (A) Caloric intake (kcal); (B) Adiposity
 230 index (%); (C) Final body weight (g); (D) Systolic blood pressure (mmHg); (E) Triglycerides (mg/dL); (F)
 231 Glucose (mg/dL); (G) Insulin (μ U/ml); and (H) HOMA-IR. Data are expressed as mean \pm standard deviation.
 232 Comparison by two-way ANOVA with Tukey post-hoc. BLE– Bergamot Leaf Extract. HSF—high sugar fat diet.
 233

234 *Renal function parameters: treatment with BLE attenuated proteinuria and improved renal function*

235 It is possible to note that the HSF group developed renal impairment when compared to the control
 236 group, characterizing by increased protein/creatinine ratio and reduced glomerular filtration rate. The treatment

237 with the extract provided full recovery of proteinuria and improved renal function, shown by increased glomerular
 238 filtration rate (Figure 2 A and B).



239
 240 **Figure 2.** Renal function in 30 weeks. (A) Protein/creatinine ratio; (B) Glomerular filtration rate– GFR (mL/min).
 241 Data are expressed as median (min-max) and mean \pm standard deviation. Comparison by two-way ANOVA with
 242 Tukey post-hoc. BLE– Bergamot Leaf Extract. HSF—high sugar fat diet.
 243

244 *Cardiac function: BLE attenuated cardiac remodeling*

245 The echocardiographic parameters are presented in the Table 1. The HSF group presented cardiac
 246 remodeling characterized by changes in morphological variables (PWT, IST, LA, LVM and LVRT), diastolic
 247 deterioration (lower EWDT and E/E') and systolic dysfunction (higher LVPWSV) in comparison to the control
 248 group. Bergamot leaf extract treated the cardiac remodeling and the deterioration of diastolic and systolic
 249 functions compared to the HSF group.

250

251 **Table 1.** Cardiac function in 30 weeks.

	Groups				Effects		
	Control	Control + BLE	HSF	HSF + BLE	Diet	BLE	Interaction
PWT (mm) ¹	1.53(1.53-1.44)	1.50(1.51-1.45)	1.79(2.04-1.58)*	1.53(1.61-1.52) \blacktriangle	0.016	0.096	0.055
IST (mm) ¹	1.53(1.53-1.50)	1.53(1.56-1.50)	1.79(2.14-1.53)*	1.60(1.62-1.55) \blacktriangle	0.036	0.220	0.128
LA(mm)	4.71 \pm 0.29	4.69 \pm 0.25	5.51 \pm 0.65*	5.05 \pm 0.57 \blacktriangle	<0.001	0.143	0.174
LVM (g)	0.69 \pm 0.09	0.73 \pm 0.17	1.03 \pm 0.20*	0.77 \pm 0.10 \blacktriangle	<0.001	0.036	0.004
LVRT	0.43 \pm 0.02	0.43 \pm 0.04	0.55 \pm 0.07*	0.42 \pm 0.02 \blacktriangle	0.002	<0.001	<0.001
LVPWSV (mm/s)	82.44 \pm 6.77	80.56 \pm 6.33	61.24 \pm 10.54*	74.25 \pm 2.80 \blacktriangle	<0.001	0.026	0.004
EWDT (ms) ¹	44.00(46.00-43.00)	46.00(46.75-44.50)	58.50(62.00-51.00)*	48.00 (51.50-44.00) \blacktriangle	<0.001	0.024	0.004
E/E'	13.92 \pm 1.42	12.85 \pm 1.56	22.94 \pm 3.71*	15.75 \pm 1.69 \blacktriangle	<0.001	<0.001	<0.001
EFS (%)	63.81 \pm 3.87	59.99 \pm 6.04	54.17 \pm 4.61*	57.01 \pm 2.91	<0.001	0.747	0.034


252

253 PWT– Diastolic thickness of the left ventricle posterior wall; IST– diastolic thickness of the interventricular
 254 septum; LA—left atrium; LVM– Left ventricle mass; LVRT– Left ventricle Relative Thickness; LVPWSV– Left
 255 ventricle posterior wall shortening velocity; EWDT– E wave deceleration time; EFS– Endocardial fractional
 256 shortening. Data expressed in mean \pm standard deviation. ¹median (interquartile range). Comparison by
 257 Comparison by two-way ANOVA with Tukey post-hoc. $p < 0.001$. HSF—high sugar fat diet. BLE–Bergamot Leaf
 258 Extract. * $p < 0.001$ vs. C; $\blacktriangle p < 0.001$ vs. HSF
 259

260

261 *Correlation between nutritional, metabolic, renal and cardiac parameters*


262 Figure 3 presents Pearson correlation among the variables. Regarding metabolic parameters,
 263 triglycerides, glucose, insulin and HOMA-IR were correlated with proteinuria, while only triglycerides were
 264 correlated with glomerular filtration rate. About the cardiac parameters, systolic blood pressure, triglycerides,
 265 glucose, insulin and HOMA-IR showed correlation.



266
 267 **Figure 3.** Correlation matrix among the variables. Positive correlations are presented in blue and negative
 268 correlations are presented in red color. Color intensity and the size of the circle are proportional to the correlation
 269 coefficients. Correlations with $p > 0,05$ were excluded from the matrix. Glomerular filtration rate– GFR; PWT–
 270 Diastolic thickness of the left ventricle posterior wall; IST– diastolic thickness of the interventricular septum;
 271 LA—left atrium; LVM– Left ventricle mass; LVRT– Left ventricle Relative Thickness; LVPWSV– Left ventricle
 272 posterior wall shortening velocity; EWDT– E wave deceleration time; EFS– Endocardial fractional shortening.
 273

274 Since triglycerides were the only metabolic parameter associated with both renal and cardiac variables,
 275 figure 4 highlights Pearson Correlation among these variables.

276
 277



278

279

280

281

282

283

284

285

286

287

Nrf2 activation

288

289

290

291

292

293

294

295

296

297


298

299

300

301

Figure 4. Pearson correlations among triglycerides and Cardiorenal metabolic syndrome parameters. (A) Triglycerides (mg/dL)/protein/creatinine ratio; (B) Triglycerides (mg/dL)/Glomerular filtration rate–GFR (mL/min); (C) Triglycerides (mg/dL)/Left atrium–LA(mm); (D) Triglycerides (mg/dL)/Endocardial fractional shortening–EFS(%); (E) Triglycerides (mg/dL)/Left Ventricle Mass (g); (F) Triglycerides (mg/dL)/Left ventricle Relative Thickness–LVRT; (G) Triglycerides (mg/dL)/Left ventricle posterior wall shortening velocity–LVPWSV (mm/s); (H) Triglycerides (mg/dL)/E Wave deceleration time–EWDT (ms); (I) Triglycerides (mg/dL)/E/E'; Pearson regression was used to examine the association between variables.



302 **Figure 5.** BLF activates the Nrf2 pathway. The graph bar shows the dose-dependent effect of BLF as Nrf2
 303 activator as determined in NRF2/ARE Responsive Luciferase Reporter HEK293 stable cell line. The main
 304 flavonoid and non flavonoid constituents of bergamot leaves as reported in Baron et al. are summarized in the two
 305 tables (Baron et al., 2021). The structure of each aglycone is depicted and linked by an arrow to the ortho-diphenol
 306 moiety which is the required structure for Nrf2 activation through a mechanism shown in the upper part of the
 307 figure and described in the text. The link arrow is labelled by an M when a phase I metabolic activation (O-
 308 demethylation and/or aromatic hydroxylation) is required for the conversion of the compound to the ortho-
 309 diphenol moiety.

310

311 4. Discussion

312 The aim of this study was to test the potential of BLE on CRMS in animals fed with a high sugar-fat diet. At
 313 the end of the experimental protocol, both groups that consumed the HSF diet presented obesity, systolic arterial
 314 hypertension, dyslipidemia, higher glucose and insulin levels and insulin resistance. These results demonstrate
 315 that the diet promoted the risk factors for CRMS in the HSF groups (Francisqueti et al., 2017). Corroborating these
 316 findings, the literature shows that a diet rich in simple carbohydrates, such as those administered to the HSF
 317 animals, due to their lower molecular weight, are absorbed more quickly, resulting in higher fat deposition. Also,
 318 this energy imbalance caused by a hypercaloric diet can impair some molecular alterations, such as insulin

319 signaling, resulting in impaired glucose transport, dysregulated lipolysis and dyslipidemia(Rodríguez-Correa et
320 al., 2020).

321 The confirmation of CRMS in the HSF group was through the increase in protein/creatinine ratio, decrease
322 in the GFR and cardiac remodeling characterized by changes in morphological variables, diastolic deterioration
323 and systolic dysfunction in relation to the control group. These results can be explained by the presence of obesity-
324 related disorders in the HSF group triggered by the chronic inflammation state common in obesity, consequence
325 of adipocyte hypertrophy and altered adipokine and adipocytokines pro-inflammatory secretion, among them,
326 insulin resistance(Bischoff et al., 2017).

327 The presence of insulin resistance appears to play an important role in both obesity-related heart and kidney
328 failures, since impaired insulin metabolic signaling reduces bioavailable nitric oxide (NO), increases oxidant
329 stress and inflammation, and activates renin-angiotensin-aldosterone system (RAAS), resulting in maladaptive
330 myocardial tissue remodeling and interstitial fibrosis that contribute to impairments in diastolic function in heart
331 and induces glomerular dysfunction and tubulointerstitial fibrosis in kidneys(Whaley-Connell and Sowers, 2012).
332 Moreover, insulin resistance is also associated with increased lipolysis in adipose tissue that releases a large
333 amount of free fatty acids (FFAs) into the bloodstream. The imbalance between the excessive influx of FFAs and
334 the saturation of oxidative capacity (mitochondrial β -oxidation) results in bioenergetic incompatibility with
335 accumulation of TG in the hepatocyte and greater mobilization to the circulation of very low-density lipoproteins
336 (VLDLs) rich in TG, leading to hypertriglyceridemia(Mashek, 2021). This condition of hypertriglyceridemia also
337 promotes ectopic accumulation of fat in non-fat-storing organs such as kidneys and heart, which induces oxidative
338 stress and promotes a mitochondrial dysfunction, intensifying the reduction-oxidation imbalance contributing to
339 the activation of pro-inflammatory, pro-fibrogenic, and pro-apoptotic pathways, causing cellular injury. Therefore
340 long-term HSF diet feeding results in obesity, metabolic syndrome, which are risk factors for CRMS(Sun et al.,
341 2020; Wali et al., 2020).

342 Furthermore, the FFAs overload also results in an increase ROS generation as a metabolism product through
343 nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation locally in adipose cells or in other
344 organs cells, aggravating the oxidative stress(Matsuda and Shimomura, 2013). The accumulation of ROS
345 contributes to vasoconstriction, inflammation and impaired vascular which contributes to the pathogenesis of
346 CRMS(Ammar et al., 2021; Rubattu et al., 2013). The increase of oxidative stress markers can lead to structural
347 changes in the myocardium, which can result in cardiac remodeling, decrease in contractility and heart
348 failure(Spinale et al., 1998). Also, increased ROS are related to reduced renal function, leading to kidney
349 hyperfiltration through compensatory mechanisms that contributes to glomerular hypertension, proteinuria or
350 even loss of function (Cachofeiro et al., 2008).

351 In opposition, animals that consumed BLE in addition to the HSF diet presented lower triglycerides, insulin
352 levels and insulin resistance compared to the group that consumed just the HSF diet. The amelioration of these
353 parameters, which are risk factors for CRMS, are in accordance with studies that evaluated the same parameters
354 with bergamot fruit, highlighting the power of leaves as a possible adjuvant in the treatment of these
355 comorbidities(Mollace et al., 2011). However, the mechanisms responsible by the positive effects of BLE are not
356 fully elucidate. Bergamot fruit and leaf extract share the same class of polyphenolic compounds, and some of
357 them, like flavones and flavanones, in higher concentrations in the leaf, showing promising results treating
358 complications associated with the HSF diet consumption(Baron et al., 2021). Some of these flavonoids, such as

359 naringin, neoeriocitrin and rutin, have been shown to exert an antiatherogenic effect on animal models and low
360 density lipoproteins (LDLs) oxidation inhibition, contributing to the potential hypolipidemic effect in the
361 BLE(Miceli et al., 2007; Mollace et al., 2011). The buteridine, naringin and melitidine of BPF are structurally
362 similar to HMG-CoA reductase substrate statins and thus can competitively inhibit HMG-CoA
363 reductase(Leopoldini et al., 2010). The flavonoids may also lower cholesterol levels by binding bile acids and
364 increasing the turnover rate of blood and liver cholesterol, reducing TG accumulation in the liver, and enhancing
365 the excretion of fecal neutral sterols and total bile acids(Miceli et al., 2007; Parafati et al., 2015). Naringin and
366 neohesperidin may reduce hepatic TG accumulation by inhibiting the activity of phosphatidate phosphohydrolase,
367 a TG synthetic enzymes and by reducing the availability of lipids for assembly of lipoproteins via reduced
368 activities of acyl CoA:cholesterol acyltransferases.

369 As above described, oxidative stress is a condition associated with cardiorenal metabolic syndrome. In this
370 sense, in order to alleviate oxidative stress, different mechanisms are activated, such as Nrf-2, increasing the
371 production of endogenous antioxidants, preventing and controlling the formation of free radicals and consequently
372 the damage caused by them(Ishii et al., 2002). By using a gene reporter cell model of NRF2 activation, we here
373 report the ability of the extract to induce, in the concentration range 100-250 μ g/ml, the Nrf2-ARE pathway which
374 regulates the expression of a large battery of genes involved in the cellular antioxidant and anti-inflammatory
375 defense as well as mitochondrial protection. Figure 5 reports the main flavonoid and non flavonoid constituents
376 of bergamot leaves(Baron et al., 2021). The structure of each aglycone is depicted and the derivatives reported in
377 the table. In the figure, each aglycone structure is linked by an arrow to the ortho-diphenol moiety which is the
378 required structure for Nrf2 activation for this class of compounds, through a mechanism shown in the upper part
379 of the figure. In particular, the di-phenol moiety is activated by an oxidative stress environment to the
380 corresponding quinone which being an electrophilic derivative it binds the thiol of KEAP-1, inducing the release
381 of NRF2 which, upon translocation at the nuclear level, binds to the antioxidant response elements (AREs) in the
382 regulatory region of target genes that encode proteins involved in redox homeostasis, xenobiotic metabolism and
383 survival responses. When a phase I metabolic activation (O-demethylation and/or aromatic hydroxylation) is
384 required for the conversion of the compound to the ortho-diphenol moiety, the link arrow is labelled by an M.
385 Eriodictyol and luteolin do not require a metabolic conversion because they already contain the ortho-diphenol
386 moiety and hence they act as direct Nrf2 activators. We believe that the overall Nrf2 activity of the extract is more
387 likely underestimated because many polyphenol compounds require a metabolic conversion which should occur
388 in vivo, mainly in liver and not in cell lines, as already demonstrated for resveratrol and sylibin which are activated
389 to the ortho-diphenol derivatives by the cytochrome P450 enzyme CYP1B1 and by CYP mediate O-
390 demethylation, respectively(Potter et al., 2002; Xie et al., 2019).

391 The polyphenol content also exerts antioxidant and inflammatory effects, as demonstrated by Baron et
392 al(Baron et al., 2021), in a mechanism that seems to be associated with inhibition of NF- κ B activation. The
393 literature reports that NF- κ B translocation to the nucleus encodes inflammatory mediators such as tumoral
394 necrosis factor alpha (TNF- α) and interleukin 1-beta (IL-1 β) and interleukin- 6 (IL-6). This inflammatory
395 condition causes serine kinase phosphorylation of insulin receptor substrate -1 or 2 (IRS-1 or IRS-2), which may
396 block insulin signaling and finally lead to the occurrence of insulin resistance(Chen et al., 2015). Therefore, the
397 improvement in insulin sensitivity can be result of the antioxidant and antiinflammatory effect of BLE, especially
398 addressed to flavanone and flavone glycosides, as well as to their aglycones, including naringin and

399 hesperidin, diosmetin, apigenin, and luteolin glycosides (Baron et al., 2021). This antioxidant and
 400 anti-inflammatory effect can also explain the protection against heart and kidney dysfunction even in the presence
 401 of hypertension, an independent factor for CRMS. Some studies of our research group showed a local antioxidant
 402 and anti-inflammatory effect of lycopene in the heart of obese animals and the same positive effect of gamma-
 403 oryzanol in the kidney of obese animals, preserving renal function (Ferron et al., 2020; Francisqueti et al., 2018).
 404 This same effect may be exerted BLE in the heart and kidney of animals from this study. Figure 6 presents a
 405 summary of the observed effects.

406 Despite there are no clinical trials evaluating the effect of bergamot leaf extract in humans, the extract may
 407 be a promising candidate in preventing and improving factors associated with the development and progression
 408 of Cardiorenal Metabolic Syndrome.

409




Figure 6. Role of Bergamot Leaf Extract in the pathophysiological process of Cardiorenal Metabolic Syndrome (CRMS). The results demonstrate that the high sugar-fat diet promoted the risk factors for CRMS in the HSF groups, such as obesity, systolic arterial hypertension, dyslipidemia, higher glucose, insulin levels and insulin resistance. The high consumption of high sugar-fat diets contributes to adipose tissue dysfunction, inflammatory pathways activation and reactive oxygen species production, promoting oxidative stress. These conditions contribute directly with CRMS development by the presence of increased protein/creatinine ratio, decreased glomerular filtration rate and cardiac remodeling characterized by changes in morphological variables, diastolic deterioration and systolic dysfunction. Bergamot (*Citrus bergamia*) Leaf Extract was efficient in controlling and treating CRMS and pathophysiological process involved with the disease. In addition, the extract was able to induce the Nrf2-ARE pathway, which regulates the expression of a large battery of genes involved in the cellular antioxidant and anti-inflammatory defense as well as mitochondrial protection.

410

411

412

5. Conclusion

413

414

415

416

417

In summary, this study showed that the HSF diet induced obesity, insulin resistance, dyslipidemia, systolic blood pressure, and cardiorenal metabolic syndrome. On the other hand, the HSF group treated with bergamot leaves extract presented amelioration on insulin resistance, dyslipidemia and cardiorenal metabolic syndrome. Therefore, it is possible to conclude that bergamot leaf extract was able to treat cardiorenal metabolic syndrome in animals fed with a high sugar-fat diet.

418

419 **6. Acknowledgments**

420 We acknowledge support by the Open APC European Project fund of the Università degli Studi di Milano
421 and São Paulo Research Foundation (Fapesp 2018/15294-3).

422

423 **7. Fundings**

424 Francesca Gado is a temporary researcher (RTDA) supported by Ministero dell'Università e della Ricerca
425 PON "Ricerca e Innovazione" 2014-2020, Azione IV.6 – "Contratti di ricerca su tematiche Green"; and São Paulo
426 Research Foundation (FAPESP) [Grant number 2018/15294-3].

427

428 **8. References**

429

430 Ammar, L.A., Nahlawi, M.I., Shayya, N.W., Ghadieh, H.E., Azar, N.S., Harb, F., Eid, A.A., 2021.

431 Immunomodulatory Approaches in Diabetes-Induced Cardiorenal Syndromes. *Front. Cardiovasc. Med.* 7.
432 <https://doi.org/10.3389/fcvm.2020.630917>

433 Anna, V.O., Mátyus, J., Sárkány, E., Horváth, A., Fodor, B., 2010. New trends in the laboratory diagnostics of
434 proteinuria and albuminuria. *Orv. Hetil.* 151, 864–869. <https://doi.org/10.1556/OH.2010.28891>

435 Baron, G., Altomare, A., Mol, M., Garcia, J.L., Correa, C., Raucci, A., Mancinelli, L., Mazzotta, S., Fumagalli,
436 L., Trunfio, G., Tucci, L., Lombardo, E., Malara, D., Janda, E., Mollace, V., Carini, M., Bombardelli, E.,
437 Aldini, G., 2021. Analytical Profile and Antioxidant and Anti-Inflammatory Activities of the Enriched
438 Polyphenol Fractions Isolated from Bergamot Fruit and Leave. *Antioxidants* 10, 141.
439 <https://doi.org/10.3390/antiox10020141>

440 Bischoff, S.C., Boirie, Y., Cederholm, T., Chourdakis, M., Cuerda, C., Delzenne, N.M., Deutz, N.E., Fouque,
441 D., Genton, L., Gil, C., Koletzko, B., Leon-Sanz, M., Shamir, R., Singer, J., Singer, P., Stroebele-
442 Benschop, N., Thorell, A., Weimann, A., Barazzoni, R., 2017. Towards a multidisciplinary approach to
443 understand and manage obesity and related diseases. *Clin. Nutr.* 36, 917–938.
444 <https://doi.org/10.1016/j.clnu.2016.11.007>

445 Cachofeiro, V., Goicochea, M., de Vinuesa, S.G., Oubiña, P., Lahera, V., Luño, J., 2008. Oxidative stress and
446 inflammation, a link between chronic kidney disease and cardiovascular disease. *Kidney Int.* 74, S4–S9.
447 <https://doi.org/10.1038/ki.2008.516>

448 Chen, L., Chen, R., Wang, H., Liang, F., 2015. Mechanisms Linking Inflammation to Insulin Resistance. *Int. J.*
449 *Endocrinol.* 2015, 1–9. <https://doi.org/10.1155/2015/508409>

450 Cuadrado, A., Manda, G., Hassan, A., Alcaraz, M.J., Barbas, C., Daiber, A., Ghezzi, P., León, R., López, M.G.,
451 Oliva, B., Pajares, M., Rojo, A.I., Robledinos-Antón, N., Valverde, A.M., Guney, E., Schmidt, H.H.H.W.,
452 2018. Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine
453 Approach. *Pharmacol. Rev.* 70, 348–383. <https://doi.org/10.1124/pr.117.014753>

454 Di Donna, L., De Luca, G., Mazzotti, F., Napoli, A., Salerno, R., Taverna, D., Sindona, G., 2009. Statin-like
455 principles of bergamot fruit (*Citrus bergamia*): Isolation of 3-hydroxymethylglutaryl flavonoid glycosides.
456 *J. Nat. Prod.* 72, 1352–1354. <https://doi.org/10.1021/np900096w>

457 Echeverría, F., Valenzuela, R., Bustamante, A., Álvarez, D., Ortiz, M., Soto-Alarcon, S.A., Muñoz, P., Corbari,
458 A., Videla, L.A., 2018. Attenuation of High-Fat Diet-Induced Rat Liver Oxidative Stress and Steatosis by

- 459 Combined Hydroxytyrosol- (HT-) Eicosapentaenoic Acid Supplementation Mainly Relies on HT. *Oxid.*
460 *Med. Cell. Longev.* 2018, 1–13. <https://doi.org/10.1155/2018/5109503>
- 461 Ferlemi, A.V., Lamari, F.N., 2016. Berry leaves: An alternative source of bioactive natural products of
462 nutritional and medicinal value. *Antioxidants* 5. <https://doi.org/10.3390/antiox5020017>
- 463 Ferron, A.J.T., Francisqueti-Ferron, F.V., De Almeida Silva, C.C.V., Bazan, S.G.Z., De Campos, D.H.S.,
464 Garcia, J.L., Ghiraldeli, L., Minatel, I.O., Correa, C.R., Moreto, F., Ferreira, A.L.A., 2020. Tomato-
465 oleoresin anti-inflammatory effect recovers obesity-induced cardiac dysfunction by modulating
466 myocardial calcium handling. *Cell. Physiol. Biochem.* 54, 1013–1025.
467 <https://doi.org/10.33594/000000284>
- 468 Formisano, C., Rigano, D., Lopatriello, A., Sirignano, C., Ramaschi, G., Arnoldi, L., Riva, A., Sardone, N.,
469 Tagliatela-Scafati, O., 2019. Detailed Phytochemical Characterization of Bergamot Polyphenolic
470 Fraction (BPF) by UPLC-DAD-MS and LC-NMR. *J. Agric. Food Chem.* 67, 3159–3167.
471 <https://doi.org/10.1021/acs.jafc.8b06591>
- 472 Francisqueti, F., Minatel, I., Ferron, A., Bazan, S., Silva, V., Garcia, J., de Campos, D., Ferreira, A., Moreto, F.,
473 Cicogna, A., Corrêa, C., 2017. Effect of Gamma-Oryzanol as Therapeutic Agent to Prevent Cardiorenal
474 Metabolic Syndrome in Animals Submitted to High Sugar-Fat Diet. *Nutrients* 9, 1299.
475 <https://doi.org/10.3390/nu9121299>
- 476 Francisqueti, F.V., Ferron, A.J.T., Hasimoto, F.K., Alves, P.H.R., Garcia, J.L., Santos, K.C., Moreto, F.,
477 Ferreira, A.L.A., Minatel, I.O., Corrêa, C.R., 2018. Gamma Oryzanol Treats Obesity-Induced Kidney
478 Injuries by Modulating the Adiponectin Receptor 2 / PPAR- α Axis. *Oxid. Med. Cell. Longev.* 2018, 1–9.
- 479 Gonc, D.F., Paola, B., Rafacho, M., Assis, B., Jaldin, G., Bruder, T., Alves, M., Silva, B., Antonio, L., Zornoff,
480 M., Alberto, S., Paiva, R. De, 2014. Vitamin D Induces Increased Systolic Arterial Pressure via Vascular
481 Reactivity and Mechanical Properties. *PLoS One* 9, 1–9. <https://doi.org/10.1371/journal.pone.0098895>
- 482 Gugliandolo, A., Bramanti, P., Mazzon, E., 2020. Activation of Nrf2 by Natural Bioactive Compounds: A
483 Promising Approach for Stroke? *Int. J. Mol. Sci.* 21, 4875. <https://doi.org/10.3390/ijms21144875>
- 484 Ishii, T., Itoh, K., Yamamoto, M., 2002. Roles of Nrf2 in activation of antioxidant enzyme genes via antioxidant
485 responsive elements. *Methods Enzymol.* 348, 182–190. [https://doi.org/10.1016/S0076-6879\(02\)48637-5](https://doi.org/10.1016/S0076-6879(02)48637-5)
- 486 Leopoldini, M., Malaj, N., Toscano, M., Sindona, G., Russo, N., 2010. On the Inhibitor Effects of Bergamot
487 Juice Flavonoids Binding to the 3-Hydroxy-3-methylglutaryl-CoA Reductase (HMGR) Enzyme. *J. Agric.*
488 *Food Chem.* 58, 10768–10773. <https://doi.org/10.1021/jf102576j>
- 489 Luvizotto, R.D.A.M., Nascimento, A.F., Imaizumi, E., Pierine, D.T., Conde, S.J., Correa, C.R., Yeum, K.-J.,
490 Ferreira, A.L. a, 2013. Lycopene supplementation modulates plasma concentrations and epididymal
491 adipose tissue mRNA of leptin, resistin and IL-6 in diet-induced obese rats. *Br. J. Nutr.* 110, 1803–9.
492 <https://doi.org/10.1017/S0007114513001256>
- 493 Mashek, D.G., 2021. Hepatic lipid droplets: A balancing act between energy storage and metabolic dysfunction
494 in NAFLD. *Mol. Metab.* 50, 101115. <https://doi.org/10.1016/j.molmet.2020.101115>
- 495 Matsuda, M., Shimomura, I., 2013. Increased oxidative stress in obesity: Implications for metabolic syndrome,
496 diabetes, hypertension, dyslipidemia, atherosclerosis, and cancer. *Obes. Res. Clin. Pract.* 7, e330–e341.
497 <https://doi.org/10.1016/j.orcp.2013.05.004>
- 498 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, T.R., Matthews, D.R., Hosker, J.P.,

- 499 Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C., 1985. Homeostasis model assessment: insulin
500 resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.
501 *Diabetologia* 28, 412–419. <https://doi.org/10.1007/BF00280883>
- 502 Miceli, N., Mondello, M.R., Monforte, M.T., Sdrafkakis, V., Dugo, P., Crupi, M.L., Taviano, M.F., De
503 Pasquale, R., Trovato, A., 2007. Hypolipidemic effects of Citrus bergamia Risso et Poiteau juice in rats
504 fed a hypercholesterolemia diet. *J. Agric. Food Chem.* 55, 10671–10677.
505 <https://doi.org/10.1021/jf071772i>
- 506 Mollace, V., Sacco, I., Janda, E., Malara, C., Ventrice, D., Colica, C., Visalli, V., Muscoli, S., Ragusa, S.,
507 Muscoli, C., Rotiroti, D., Romeo, F., 2011. Hypolipemic and hypoglycaemic activity of bergamot
508 polyphenols: From animal models to human studies. *Fitoterapia* 82, 309–316.
509 <https://doi.org/10.1016/j.fitote.2010.10.014>
- 510 Musolino, V., Gliozzi, M., Scarano, F., Bosco, F., Scicchitano, M., Nucera, S., Carresi, C., Ruga, S., Zito, M.C.,
511 Maiuolo, J., Macrì, R., Amodio, N., Juli, G., Tassone, P., Mollace, R., Caffrey, R., Marioneaux, J.,
512 Walker, R., Ehrlich, J., Palma, E., Muscoli, C., Bedossa, P., Salvemini, D., Mollace, V., Sanyal, A.J.,
513 2020. Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model
514 of Non-Alcoholic Fatty Liver Disease. *Sci. Rep.* 10, 1–14. <https://doi.org/10.1038/s41598-020-59485-3>
- 515 Parafati, M., Lascala, A., Morittu, V.M., Trimboli, F., Rizzuto, A., Brunelli, E., Coscarelli, F., Costa, N., Britti,
516 D., Ehrlich, J., Isidoro, C., Mollace, V., Janda, E., 2015. Bergamot polyphenol fraction prevents
517 nonalcoholic fatty liver disease via stimulation of lipophagy in cafeteria diet-induced rat model of
518 metabolic syndrome. *J. Nutr. Biochem.* 26, 938–948. <https://doi.org/10.1016/j.jnutbio.2015.03.008>
- 519 Popkin, B.M., Adair, L.S., Ng, S.W., 2012. NOW AND THEN: The Global Nutrition Transition: The
520 Pandemic of Obesity in Developing Countries. *Nutr. Rev.* 70, 3–21. <https://doi.org/10.1111/j.1753-4887.2011.00456.x>
- 522 Potter, G.A., Patterson, L.H., Wanogho, E., Perry, P.J., Butler, P.C., Ijaz, T., Ruparelia, K.C., Lamb, J.H.,
523 Farmer, P.B., Stanley, L.A., Burke, M.D., 2002. The cancer preventative agent resveratrol is converted to
524 the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. *Br. J. Cancer* 86, 774–778.
525 <https://doi.org/10.1038/sj.bjc.6600197>
- 526 Rangaswami, J., Bhalla, V., Blair, J.E.A., Chang, T.I., Costa, S., Lentine, K.L., Lerma, E. V., Mezue, K.,
527 Molitch, M., Mullens, W., Ronco, C., Tang, W.H.W., McCullough, P.A., 2019. Cardiorenal Syndrome:
528 Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the
529 American Heart Association. *Circulation* 139. <https://doi.org/10.1161/CIR.0000000000000664>
- 530 Risitano, R., Currò, M., Cirmi, S., Ferlazzo, N., Campiglia, P., Caccamo, D., Ientile, R., Navarra, M., 2014.
531 Flavonoid fraction of bergamot juice reduces LPS-induced inflammatory response through SIRT1-
532 mediated NF- κ B inhibition in THP-1 monocytes. *PLoS One* 9, 1–9.
533 <https://doi.org/10.1371/journal.pone.0107431>
- 534 Rodríguez-Correa, E., González-Pérez, I., Clavel-Pérez, P.I., Contreras-Vargas, Y., Carvajal, K., 2020.
535 Biochemical and nutritional overview of diet-induced metabolic syndrome models in rats: what is the best
536 choice? *Nutr. Diabetes* 10. <https://doi.org/10.1038/s41387-020-0127-4>
- 537 Romão Junior, J.E., 2004. Doença Renal Crônica: Definição, Epidemiologia e Classificação. *J. Bras. Nefrol.* 26,
538 1–3.

- 539 Rubattu, S., Mennuni, S., Testa, M., Mennuni, M., Pierelli, G., Pagliaro, B., Gabriele, E., Coluccia, R., Autore,
540 C., Volpe, M., 2013. Pathogenesis of Chronic Cardiorenal Syndrome: Is There a Role for Oxidative
541 Stress? *Int. J. Mol. Sci.* 14, 23011–23032. <https://doi.org/10.3390/ijms141123011>
- 542 Sahn, D.J., DeMaria, A., Kisslo, J., Weyman, A., 1978. Recommendations regarding quantitation in M-mode
543 echocardiography: Results of a survey of echocardiographic measurements. *Circulation* 58, 1072–1083.
544 <https://doi.org/10.1161/01.CIR.58.6.1072>
- 545 Silva Junior, G.B. da, Bentes, A.C.S.N., Daher, E.D.F., Matos, S.M.A. de, 2017. Obesity and kidney disease. *J.*
546 *Bras. Nefrol.* 39. <https://doi.org/10.5935/0101-2800.20170011>
- 547 Spinale, F.G., Coker, M.L., Thomas, C. V., Walker, J.D., Mukherjee, R., Hebbbar, L., 1998. Time-Dependent
548 Changes in Matrix Metalloproteinase Activity and Expression During the Progression of Congestive Heart
549 Failure. *Circ. Res.* 82, 482–495. <https://doi.org/10.1161/01.RES.82.4.482>
- 550 Sun, Y., Ge, X., Li, Xue, He, J., Wei, X., Du, J., Sun, J., Li, Xin, Xun, Z., Liu, W., Zhang, H., Wang, Z.-Y., Li,
551 Y.C., 2020. High-fat diet promotes renal injury by inducing oxidative stress and mitochondrial
552 dysfunction. *Cell Death Dis.* 11, 914. <https://doi.org/10.1038/s41419-020-03122-4>
- 553 van der Velde, M., Matsushita, K., Coresh, J., Astor, B.C., Woodward, M., Levey, A.S., de Jong, P.E.,
554 Gansevoort, R.T., 2011. Lower estimated glomerular filtration rate and higher albuminuria are associated
555 with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts.
556 *Kidney Int.* 79, 1341–1352. <https://doi.org/10.1038/ki.2010.536>
- 557 Wali, J.A., Jarzebska, N., Raubenheimer, D., Simpson, S.J., Rodionov, R.N., O’Sullivan, J.F., 2020. Cardio-
558 Metabolic Effects of High-Fat Diets and Their Underlying Mechanisms—A Narrative Review. *Nutrients*
559 12, 1505. <https://doi.org/10.3390/nu12051505>
- 560 Whaley-Connell, A., Sowers, J.R., 2014. The CardioRenal Metabolic Syndrome. *J. Am. Soc. Hypertens.* 8, 604–
561 606. <https://doi.org/10.1016/j.jash.2014.07.003>
- 562 Whaley-Connell, A., Sowers, J.R., 2012. Oxidative Stress in the Cardiorenal Metabolic Syndrome. *Curr.*
563 *Hypertens. Rep.* 14, 360–365. <https://doi.org/10.1007/s11906-012-0279-2>
- 564 Wu, X., Huang, L., Liu, J., 2021. Relationship between oxidative stress and nuclear factor-erythroid-2-related
565 factor 2 signaling in diabetic cardiomyopathy (Review). *Exp. Ther. Med.* 22, 678.
566 <https://doi.org/10.3892/etm.2021.10110>
- 567 Xie, Zhang, Zhang, Yuan, 2019. Metabolism, Transport and Drug–Drug Interactions of Silymarin. *Molecules*
568 24, 3693. <https://doi.org/10.3390/molecules24203693>
- 569

Bergamot leaf extract promoted lower dyslipidemia and Insulin Resistance levels.

The extract treated cardiorenal metabolic syndrome, improving organ's function.

Bergamot leaf extract stimulates Nrf2 activation.

Journal Pre-proof